# US 6,730,687 B1 · Substituted benzylthiazolidine-2, 4-dione derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,687 B1
- Document ID: US6730687B1
- Status: Granted
- Kind: B1
- Application number: 10/049,645
- Filed: 2002-02-25
- Granted: 2004-05-04
- Earliest claimed: 1999-08-23
- Assignees: Kyorin Pharmaceutical Co., Ltd.
- Inventors: Hiroyuki Miyachi; Masahiro Nomura; Takahiro Tanase; Koji Murakami; Masaki Tsunoda
- Web page: https://patentgrep.com/patent/US6730687B1

## CPC

- C07D 277/34: Oxygen atoms
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides novel substituted benzylthiazolidine-2,4-dione derivatives that bind to receptor to activate as ligands of human peroxisome proliferator-activated receptor (PPAR) and exhibit blood glucose-decreasing action and lipid-decreasing action, and processes for preparing them. It relates to substituted benzylthiazolidine-2,4-dione derivatives represented by the general formula (1) [wherein the bond mode of A denotes —CH2CONH—, —NHCONH—, —CH2CH2CO— or —NHCOCH2—, and B denotes a lower alkyl group with carbon atoms of 1 to 4, lower alkoxy group with carbon atoms of 1 to 3, halogen atom, trifluoromethyl group, trifluoromethoxy group, phenyl group which is unsubstituted or may have substituents, phenoxy group which is unsubstituted or may have substituents or benzyloxy group which is unsubstituted or may have substituents], their medicinally acceptable salts, their hydrates and processes for preparing them.

## Claims

### Claim 1

A substituted benzylthiazolidine-2,4-dione derivative represented by a general formula (1)
wherein the bond mode of A denotes —CH2CONH—, —NHCONH—, —CH2CH2CO— or —NHCOCH2—, and B denotes a lower alkyl group with carbon atoms of 1 to 4, lower alkoxy group with carbon atoms of 1 to 3, halogen atom, trifluoromethyl group, trifluoro-methoxy group, phenyl group which is unsubstituted or may have substituents, phenoxy group which is unsubstituted or may have substituents or benzyloxy group which is unsubstituted or may have substituents, their medicinally acceptable salts and their hydrates.

### Claim 2 (depends on 1)

Substituted benzylthiazolidine-2,4-dione derivatives, their medicinally acceptable salts and their hydrates of claim 1, wherein the bond mode of A is —CH2CONH—.

### Claim 3 (depends on 1)

Substituted benzylthiazolidine-2,4-dione derivatives, their medicinally acceptable salts and their hydrates of claim 1, wherein the bond mode of A is —NHCONH—.

### Claim 4 (depends on 1)

Substituted benzylthiazolidine-2,4-dione derivatives, their medicinally acceptable salts and their hydrates of claim 1, wherein the bond mode of A is —NHCOCH2—.

### Claim 5 (depends on 1)

Substituted benzylthiazolidine-2,4-dione derivatives, their medicinally acceptable salts and their hydrates of claim 1, wherein the bond mode of A is —CH2CH2CO—.

### Claim 6 (depends on 1)

Compounds, their medicinally acceptable salts and their hydrates of claim 1, wherein one of the compounds is N-[2-methoxy-5-[(2,4-dioxothiazolidin-5-yl)methyl]phenyl]-2-[4-(trifluoromethyl)phenyl]acetamide.

### Claim 7 (depends on 1)

Compounds, their medicinally acceptable salts and their hydrates of claim 1, wherein one of the compounds is 5-[[4-methoxy-3-[3-[4-(trifluoromethyl)phenyl]ureido]phenyl]-methyl]thiazolidine-2,4-dione.

### Claim 8 (depends on 1)

Compounds, their medicinally acceptable salts and their hydrates of claim 1, wherein one of the compounds is N-[4-(trifluoromethyl)phenyl]-2-[5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxyphenyl]acetamide.

### Claim 9 (depends on 1)

Compounds, their medicinally acceptable salts and their hydrates of claim 1, wherein one of the compounds is 5-[[3-[3-[4-(trifluoromethyl)phenyl]propanoyl]-4-methoxyphenyl]methyl]-thiazolidine-2,4-dione.

### Claim 10 (depends on 1)

A medicinal composition, comprising at least one substituted benzylthiazolidine-2,4-dione derivative according to claim 1 and a suitable carrier.

### Claim 11 (depends on 1)

A process for preparing a medicinal composition, comprising
contacting at least one substituted benzylthiazolidine-2,4-dione derivative according to claim 1 with a suitable carrier.
